Phase 3 REFLECT Trial in Patients with Unresectable Hepatocellular Carcinoma

An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.